Feasibility and Cardiac Safety of Pegylated Liposomal Doxorubicin plus Trastuzumab in Heavily Pretreated Patients with Recurrent HER2-Overexpressing Metastatic Breast Cancer
Eleni Andreopoulou(Cornell University), Franco M. Muggia(NYU Langone Health), Darci Gaiotti(New York University), Ruth Oratz(NYU Langone Health), Stephen Chia(BC Cancer Agency), Robin S. Freedberg(Columbia University Irving Medical Center), Eugene S. Kim(Cedars-Sinai Medical Center), Charles L. Vogel(Cancer Research Institute), Andrea Downey(University of New Mexico), Matthew Volm(Columbia University Irving Medical Center)
Cited by 31
Related Papers
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
|Journal of Clinical Oncology|1997|652
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
|Nature|2014|642
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594
Current Landscape of Immunotherapy in Breast Cancer
|JAMA Oncology|2019|409